METS MATTERS
In This Issue
WHAT'S NEW

TAPUR 

In mid March, American Society of Clinical Oncology (ASCO) rolled out its first clinical trial. The goal of the trial is to give us access to FDA-approved targeted drugs that match a genomic abnormality, even when the drugs have not been approved to treat metastatic breast cancer (MBC).

READ MORE HERE


TESTING IN METASTATIC BREAST CANCER

A recent workshop given by Dr. Ruth Oratz at Living Beyond Breast Cancer's annual conference for those living with metastatic breast cancer offered information on how oncologists use tests to determine the best course of action to treat metastatic breast cancer.  Dr. Oratz is a clinical professor and firm chief of the Department of Medicine at NYU Langone Medical Center in New York City.
Resources
Call SHARE
Speak with a metastatic peer: 844-ASK-SHARE. O, habla con una sobriviviente que tiene cancer de seno metastatico: (866) 891-2392
National Resource Guide
SHARE's Helpline has a 400 page national resource guide-- call us to get additional resources!
Clinical Trials
For all clinical trials currently recruiting MBC patients: go  HERE

When searching trials for metastatic disease, check off your subtype and trials that you may be eligible for will be filtered. Please note there are also trials related to support and education, relationships, pain management as well as vaccines and immunotherapy. 

NBCC's Clinical Trial Partnerships for women living with metastatic disease: go HERE


American Cancer Society Clinical Trials Matching Service: 1-800-970-7848 
Upcoming Programs
UPCOMING WEBINARS:

BEYOND BRCA MUTATIONS: WHAT'S NEW IN THE WORLD OF GENETIC TESTING?

Dr. Mark Robson, Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center, will present a medical update regarding the latest developments in genetic testing as it relates to breast and ovarian cancer.  Topics will include non-BRCA mutations, including both high-penetrance and so-called moderate penetrance mutations, and a framework for management of these. 
Presented in collaboration with FORCE.

TUESDAY JULY 19
2:00 - 3:00 PM ET

REGISTER HERE

LIFESTYLE CHANGES TO HELP DEAL WITH THE STRESS OF CANCER

Beth Taubes, RN, OCN, CBCN, is an oncology nurse with over 30 years of experience and certification as a health coach. Her talk will address ways of coping with stress, getting motivated, changing habits, and overcoming barriers to change.  Beth will help you find your own personal motivator to eat well, move well, and sleep well.  Q&A period will follow. 

WEDNESDAY JULY 27
12:30 - 1:30 PM ET

REGISTER HERE

PAST WEBINARS:

REPORT FROM ASCO: Focusing on MBC
Click Here to View Webinar

FINDING A CLINICAL TRIAL THAT'S RIGHT FOR YOU
Click Here To View Webinar
MBC Alliance Update
The Metastatic Breast Cancer Alliance is working on numerous initiatives to increase knowledge, build understanding and further research.  SHARE is honored to serve on the Information Task Force working on a project to enable better communication between health care providers and patients. For more information about MBCA, go to MBCAlliance.org.
9 Telephone Support Groups: Choose What Works for You
Connecting with others living with MBC can help you gather information about treatment, dealing with side effects and coping with the fear and anxiety that a metastatic diagnosis brings.  

SHARE offers 9 Telephone Support Group sessions each month in English and 2 in Spanish.  There are also 2 in-person sessions each month in our NYC office.  

A group meets every Monday at 4 PM ET and the first four Thursdays of the month at 6 PM ET.  CLICK HERE FOR MORE INFORMATION
Want to Help Out?
SHARE offers Helpline and Group support  for women living with metastatic breast cancer.  We currently have 8 active volunteers who are quite busy as calls to the Helpline are continuously increasing. 

We provide training for both Helpline volunteers and support group facilitators.  

Training is about 2-3 hours and can take place via webinar.  If you are interested, please email Christine. 
STAY CONNECTED: